FDA scrutiny of misleading compounded GLP-1 promotion also raises the value of platforms that clearly separate clinical prescribing from product advertising
As a result, patients may develop gout, a painful inflammatory condition that can significantly impact quality of life
Your first step is to work with your doctor to understand the exact reason for the denial
It is important to note that semaglutide is not approved for use with type 1 diabetes or diabetic ketoacidosis
Glucagon-like peptide-1 (GLP-1) receptor agonists aka the -tides, GLP analogs, incretin mimetics *The FDA has approved the use of -glutides to reduce the risk of major cardiovascular events (myocardial infarction, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
human relevance is not established, but the labels contraindicate use with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2